Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.

Br J Haematol · 2008 · PMC2440525 · PMID 18477046

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantP ≤ 0·01actually significant

The Logrank test was used to analyse the significance of the differences between TTE of treated and control tumour groups, with differences deemed significant (*) at 0·01 ≤ P ≤ 0·05, and highly significant (**) at P ≤ 0·01.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.